https://www.hereirmo.com/2026/09/09/fda-approves-rasonque-pancreatic-cancer/
FDA approves RASONQUE for pancreatic cancer
Sep 9, 2026 - The FDA approved RASONQUE (daraxonrasib) on Aug 26, the first RAS-targeted pill for metastatic pancreatic cancer, based on a 500-patient trial.
pancreatic cancerfdaapprovesrasonque
https://lonevi.com/articles/rasonque-daraxonrasib-first-ras-on-inhibitor-fda
Rasonque (daraxonrasib): first broad RAS(ON) inhibitor approved by the FDA | Lonevi
Oct 6, 2026 - The FDA approved daraxonrasib for metastatic pancreatic adenocarcinoma. Median overall survival 13.2 vs 6.7 months. The trial figures, the toxicity, and the...
by therasonquedaraxonrasibfirstbroad
https://www.pharmtech.com/view/rasonque-s-60-survival-benefit-what-it-means-for-oncology-pipelines
Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines | Pharmaceutical Technology
Oct 5, 2026 - FDA approves Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, validating RAS(ON) inhibition for future drug...
what it meanspharmaceutical technologyrasonquesurvivalbenefit